Rheumatoid Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2017
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded with efficacious biologics, including blockbuster tumor necrosis factor alpha (TNF-alpha) inhibitors Amgen’s Enbrel, AbbVie’s Humira, and Janssen’s Remicade, as well as non-TNF-alpha inhibitors such as Bristol-Myers Squibb’s Orencia, Roche’s/Genentech’s Rituxan and Actemra. In addition, Pfizer’s Jak inhibitor Xeljanz, the first targeted oral molecule approved for RA, has been approved for almost five years in the United States and is gaining steady uptake in early lines of therapy.
QUESTIONS ANSWERED
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed RA patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed RA patients?
- How have non-TNF-alpha inhibitor biologics and Xeljanz been integrated into the treatment algorithm? What proportion of RA patients receive drug therapy within three years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within three years of diagnosis?
- What percentage of RA patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with RA?
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Unmet Need – Unmet Need – Unresectable Locally Advanced or Metastatic Bladder Cancer (US/EU)
The unresectable locally advanced or metastatic bladder cancer treatment landscape continues to evolve, driven by the integration of immunotherapy, targeted agents, and antibody–drug conjugates (…
